Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
188 hedge funds and large institutions have $3.5B invested in Blueprint Medicines in 2018 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 64 increasing their positions, 64 reducing their positions, and 26 closing their positions.
35% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 26
23% more capital invested
Capital invested by funds: $2.84B → $3.5B (+$658M)
4% more funds holding
Funds holding: 181 → 188 (+7)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 64
0.03% less ownership
Funds ownership: 102.23% → 102.2% (-0.03%)
34% less call options, than puts
Call options by funds: $13.9M | Put options by funds: $20.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$44.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$41.4M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$39.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$47.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$28.8M |
| 3 |
Morgan Stanley
New York
|
-$17.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.5M |
| 5 |
Two Sigma Investments
New York
|
-$16.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
201
Vident Investment Advisory
Alpharetta,
Georgia
| – | -$449K | -7,077 | Closed |
|
|
AB
202
Amalgamated Bank
New York
| – | -$401K | -6,321 | Closed |
|
203
Walleye Trading
New York
| – | -$314K | -4,511 | Closed |
|
204
Simplex Trading
Chicago,
Illinois
| – | -$312K | -4,484 | Closed |
|
205
Jane Street
New York
| – | -$206K | -3,246 | Closed |
|
|
WG
206
Winton Group
London,
United Kingdom
| – | -$201K | -3,170 | Closed |
|
207
Parallax Volatility Advisers
San Francisco,
California
| – | -$194K | -2,785 | Closed |
|
|
PIA
208
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$46K | -718 | Closed |
|
|
JG
209
Jefferies Group
New York
| – | -$32K | -500 | Closed |
|
|
MA
210
MUFG Americas
New York
| – | -$10K | -150 | Closed |
|
|
SWM
211
SeaCrest Wealth Management
Purchase,
New York
| – | -$6K | -91 | Closed |
|
|
PA
212
Parallel Advisors
San Francisco,
California
| – | -$1K | -16 | Closed |
|
|
FGAM
213
Financial Gravity Asset Management
Lakeway,
Texas
| – | +$139 | +2 | +50% |
|
BPMC Hedge Fund Activity: Q3 2018 in Review
188 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2018, worth a combined $3.5B — up 23% from $2.84B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new BPMC positions and 26 closed out — a net gain of 9 holders — while 64 added to existing stakes and 64 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $44.7M. The largest seller was Fidelity International, exiting entirely with an estimated $47.2M sold.
- 188 institutional investors held Blueprint Medicines (BPMC) as of Q3 2018, up from 181 in Q2 2018.
- Funds reported $3.5B of Blueprint Medicines stock for Q3 2018, up 23% quarter-over-quarter.
- 35 funds opened new Blueprint Medicines positions in Q3 2018 and 26 closed out, a net change of +9 holders.
- The largest Blueprint Medicines buyer in Q3 2018 was Eagle Asset Management, an estimated $44.7M added.
- The largest Blueprint Medicines seller in Q3 2018 was Fidelity International, an estimated $47.2M sold.
Based on aggregated 13F filings for Q3 2018.